(Q30432945)

19 October 2017

Caffeine and progression of Parkinson disease (English)

1 reference

19 October 2017

1 reference

3

Robert A Hauser

1 reference

19 October 2017

Christopher Swearingen

object named as

Swearingen CJ

1 reference

19 October 2017

Michael Jeffrey Aminoff

5

object named as

Michael J Aminoff

1 reference

19 October 2017

David K Simon

1

1 reference

19 October 2017

Joel M Trugman

4

1 reference

19 October 2017

Carlos Singer

6

1 reference

19 October 2017

Daniel Truong

7

1 reference

19 October 2017

Barbara C Tilley

8

1 reference

19 October 2017

NET-D Investigators

9

1 reference

19 October 2017

1 July 2008

1 reference

Clinical Neuropharmacology

19 October 2017

1 reference

19 October 2017

31

1 reference

19 October 2017

4

1 reference

19 October 2017

189-196

1 reference

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

19 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

A responsive outcome for Parkinson's disease neuroprotection futility studies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Opposite actions of caffeine and creatine on muscle relaxation time in humans

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Association of coffee and caffeine intake with the risk of Parkinson disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Actions of caffeine in the brain with special reference to factors that contribute to its widespread use.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Caffeine counteracts the ergogenic action of muscle creatine loading.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3056438

10.1097/WNF.0B013E31815A3F03

26 November 2018

Identifiers

DOI

1 reference

19 October 2017

1 reference

19 October 2017

PubMed publication ID

18670242

1 reference